Peyote therapy

What peyote is

Peyote is a small, spineless, blue-green cactus that grows in a narrow band of limestone soil in south Texas and northern Mexico. Its active compound is mescaline (3,4,5-trimethoxyphenethylamine), a phenethylamine psychedelic structurally similar to amphetamines but pharmacologically closer to the classic psychedelics, acting primarily as a 5-HT_2A receptor partial agonist. A typical ceremonial dose is 4–12 dried "buttons" (the crowns of the cactus, harvested and dried), containing on the order of 200–500 mg of mescaline total.

Peyote produces a long experience — 10–12 hours of effect — with strong visual, emotional, and somatic components. The subjective character is closer to a traditional classic psychedelic experience than to a dissociative or empathogen.

The Native American Church and AIRFA § 1996a

Peyote has been used ceremonially in the American Southwest and in Mexico for at least 5,700 years, based on carbon-dated dried buttons recovered from Texas archaeological sites. The modern pan-tribal Native American Church (NAC) coalesced in the late 19th and early 20th centuries, drawing on both Mexican and Plains traditions.

The current legal framework for ceremonial peyote use is the product of a long constitutional fight:

• 1965: Federal regulation first exempts peyote use "by members of the Native American Church in connection with the religious ceremonies of the church" (21 CFR 1307.31).
• 1990, Employment Division v. Smith: The US Supreme Court held that generally applicable drug laws do not violate the Free Exercise Clause — a ruling that erased First Amendment protection for peyote users fired from state jobs.¹
• 1993: Congress passes the Religious Freedom Restoration Act (RFRA) in response, restoring the pre-Smith compelling-interest test at the federal level.
• 1994: Congress passes the AIRFA Amendments (P.L. 103-344), codified at 42 U.S.C. § 1996a, which specifically provide that "the use, possession, or transportation of peyote by an Indian for bona fide traditional ceremonial purposes in connection with the practice of a traditional Indian religion is lawful, and shall not be prohibited by the United States or any State."¹

AIRFA’s exemption is narrower than it looks. It protects Indians — legally, members of federally recognized tribes — and their bona fide ceremonial use. It does not automatically cover non-Native NAC members, and the NAC itself is no longer named in the statutory text. For non-recognized Indians and non-Indians practicing traditional Indian peyote religions, protection is likely to rest on RFRA as interpreted in Gonzales v. O Centro Espírita Beneficente União do Vegetal (2006).⁵

The conservation crisis

Peyote grows extremely slowly: a plant takes roughly a decade to reach harvestable size, and when the crown is cut too aggressively (leaving no root mass to regenerate) the plant dies. All legal US harvest is done by a small number of state-licensed peyoteros — as of the mid-2020s, fewer than a dozen active licensees — who sell exclusively to NAC chapters.

The Indigenous Peyote Conservation Initiative (IPCI), launched by the National Council of Native American Churches and the Riverstyx Foundation, runs conservation work on a 605-acre preserve in south Texas focused on seed banking, sustainable harvest research, and cultural education. IPCI’s public position is that peyote conservation and Native religious sovereignty are inseparable issues.

Decriminalization debates — and why peyote is usually excluded

The entheogen decriminalization movement that began with Denver’s psilocybin-only measure in 2019 and has since spread to Oakland, Santa Cruz, Ann Arbor, Seattle, Washington DC, and Colorado statewide has run directly into peyote politics:

• Oakland, June 2019. The original Decriminalize Nature resolution included peyote. After formal objections from NAC leaders, Decriminalize Nature issued a policy excluding peyote from its model language nationally.
• Colorado, 2022. Proposition 122 (the Natural Medicine Health Act) defines "natural medicine" to include psilocybin, psilocin, DMT, ibogaine, and mescaline — but excludes mescaline derived from peyote. Synthetic mescaline and San Pedro-sourced mescaline are potentially covered after a 2026 advisory-board review; peyote is not.
• Oregon, 2020. Measure 109 covers psilocybin only and explicitly excludes peyote.
• Navajo Nation, 2023–2025. President Buu Nygren’s November 2023 proclamation and the Navajo Nation Council’s 2025 resolution both formally oppose federal and state decriminalization of peyote, calling for partnership with tribes on conservation policy and sacred-site protections instead.⁴

The consistent Indigenous position across these debates is not that non-Natives should never engage with mescaline — many groups explicitly support access to San Pedro or synthetic mescaline — but that peyote specifically should remain reserved for its traditional ceremonial purpose until conservation and supply questions are resolved.

Evidence for clinical use

There is no modern Phase 2 or Phase 3 pharmaceutical trial of peyote or of pure mescaline. This is a striking absence — mescaline was the molecule Humphry Osmond coined the word "psychedelic" around in 1957, and it was a central subject of 1950s–60s psychiatric research — but the re-emergence of the field has centered on psilocybin and LSD instead.

• Epidemiological data. Surveys of NAC members consistently report that regular ceremonial peyote use is not associated with cognitive impairment, psychological distress, or substance abuse; Halpern et al. 2005 (Navajo NAC members vs. matched controls) is the most-cited example.²
• Case-series and open-label work. Limited published observational work on mescaline for depression and anxiety; no randomized controlled trials of adequate size.
• Research activity in 2024-26. A small number of synthetic-mescaline programs (e.g., Journey Clinical, academic researchers at Maastricht and elsewhere) are exploring mescaline pharmacokinetics and tolerability, but none are at Phase 2b efficacy-trial stage as of this writing.

Safety & side effects

At ceremonial doses, peyote’s acute safety profile in monitored settings is broadly similar to other classic psychedelics. Key points:

• Cardiovascular. Mescaline raises blood pressure and heart rate; not safe for people with uncontrolled hypertension or recent cardiovascular events.
• Nausea and vomiting. Peyote is famously unpalatable; vomiting early in the experience is common and in many ceremonial contexts is considered purificatory.
• Serotonergic interactions. As with other serotonergic psychedelics, combination with SSRIs, SNRIs, MAOIs, tramadol, and other serotonergic agents carries real risk; MAOI combinations are particularly dangerous.
• Psychological. Long duration means extended emotional intensity. Contraindicated in personal or family history of primary psychotic or manic disorders.
• Pregnancy. Contraindicated; no adequate safety data.

How to actually access it legally

For Indians practicing a traditional Indian religion: NAC chapter membership, with peyote supplied through the licensed Texas distribution chain, is the established legal path. Contact tribal religious authorities or the National Council of Native American Churches for guidance.

For everyone else: there is no legal US pathway to peyote that does not run through NAC ceremony within the AIRFA framework. The practical alternatives for non-Native use are:

• Synthetic mescaline. Not a plant; not a conservation concern; Schedule I and not widely accessible outside of clinical research.
• San Pedro / Wachuma (Echinopsis pachanoi) and Peruvian Torch (E. peruviana) — mescaline-containing columnar cacti that grow quickly, cultivate easily, and are legal to grow ornamentally in the US. Preparation for consumption is controlled.
• International retreats (e.g., San Pedro ceremonies in Peru and Ecuador) where legal frameworks differ from the US.

Preparation & integration

NAC ceremonies have their own structure for preparation and integration that is embedded in the tradition and cannot be substituted by secular integration therapy. For non-Native use of mescaline (from San Pedro or synthetic), the standard psychedelic integration framework applies — 10–12 hours of experience is a meaningful block, and both preparation and post-session support materially affect outcomes.